ReviewArchives of gynecology and obstetrics2024
Prenatal parvovirus B19 infection.
Review in Archives of gynecology and obstetrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Transplacental Infection: Frequency, Testing, and Treatment.Deutsches Arzteblatt international · 2026Review
- Metagenomic next-generation sequencing for efficient detection of human parvovirus B19 in amniotic fluid: a case study of diagnosis and prenatal management of fetal infection.BMC pregnancy and childbirth · 2026Article
- Cellular determinants of parvovirus B19 susceptibility in the human placenta.PLoS pathogens · 2026Article
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- Insights into parvovirus B19 clinical and virological dynamics among blood donors.Le infezioni in medicina · 2026Article
- Congenital Viral Infection Risk: The Role of Parvovirus B19 and Cytomegalovirus Molecular Genetic Testing.International journal of molecular sciences · 2025Article
- Maternal health status is associated with paired maternal and cord blood virome and mother-to-infant transmission.NPJ biofilms and microbiomes · 2025Article
- Pediatrics advances in 2024: choices in allergy, cardiology, critical care, endocrinology, gastroenterology, immunology, infectious diseases, neonatology, nephrology, neurology, nutrition, palliative care respiratory tract illnesses, and social media.Italian journal of pediatrics · 2025Review
- Seroepidemiological Study of Parvovirus B19 Infection Among Pregnant Women Attending Ayatollah Rohani Hospital in Babol, Iran: A Cross-Sectional Study.Health science reports · 2025Article
- Is parvovirus B19 infection upsurge in 2023-2024 associated with adverse pregnancy outcome?Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2025Article
- Congenital Parvovirus B19 During the 2024 European Resurgence: A Prospective Single-Centre Cohort Study.Pathogens (Basel, Switzerland) · 2025Article
- Second trimester soft markers: still worth to be mentioned?Archives of gynecology and obstetrics · 2025Review
- Reproducibility of fetal ultrasound doppler parameters used for growth assessment.Archives of gynecology and obstetrics · 2025Article
- Epidemiology of Parvovirus B19 Infection In an Italian Metropolitan Area, 2012-2024: COVID-19 Pre-Pandemic, Pandemic and Post-Pandemic Trends.Journal of medical virology · 2025Article
- Retrospective and Prospective Surveillance and Clinical Presentation of Parvovirus B19 in Veneto, Italy, 2024.Microorganisms · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parvovirus B19 (B19V) causes erythema infectiosum, a.k.a., fifth disease. This disease primarily affects children. It is generally self-limiting and subsides after 1-2 weeks. In pregnancy, the virus can cross the placenta and result in a fetal infection. This may lead to severe fetal anemia, hydrops fetalis, a miscarriage, or intrauterine fetal death. The risk of long-term sequelae also appears to be increased. About one-third of pregnant women are not immune to B19V and, therefore, are at risk to contract a primary infection. The seroconversion rate during pregnancy is generally around 1-2%. During a primary infection, maternal-fetal transplacental transmission of B19V occurs in about 30-50% of the cases and the risk of fetal infection increases with advancing gestational age. The risk of severe fetal anemia or hydrops is around 3-4% overall and is around 6-7% if the primary infection occurs before 20 weeks' gestation. Fetal monitoring in women with a primary B19V infection includes regular ultrasound examinations looking for evidence of hydrops fetalis and Doppler measurements of the middle cerebral artery peak velocity. Fetal blood sampling is performed if a significant anemia is suspected and, if such is found, an intrauterine blood transfusion is needed. This article provides an overview of the epidemiology, pathogenesis, clinical manifestations, diagnostic methods, and management of B19V infection during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.